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Open access under CC BY license.Our understanding of immunity has historically been
informed by studying heritable mutations in both
the adaptive and innate immune responses, including
primary immunodeficiency and autoimmune diseases.
Recent advances achieved through the application of
genomic and epigenomic approaches are reshaping
the study of immune dysfunction and opening up new
avenues for therapeutic interventions. Moreover, apply-
ing genomic techniques to resolve functionally impor-
tant genetic variation between individuals is providing
new insights into immune function in health. This
review describes progress in the study of rare variants
and primary immunodeficiency diseases arising from
whole-exome sequencing (WES), and discusses the
application, success, and challenges of applying ge-
nome-wide association studies (GWAS) to disorders
of immune function and how they may inform more
rational use of therapeutics. In addition, the application
of expression quantitative-trait mapping to immune
phenotypes, progress in understanding MHC disease
associations, and insights into epigenetic mechanisms
at the interface of immunity and the environment are
reviewed.
Genetic variation and the immune system: in health and
disease
Effective immune function is critical to health, and dysre-
gulation underlies a large proportion of human diseases.
Elucidation of the genetic basis of rare heritable diseases
involving deficiencies in the innate and adaptive immune
response have been highly informative in advancing our
understanding of both disease mechanisms and of the
fundamental processes underpinning immunity (Box 1,
Figures 1 and 2) [1–3]. Current genomic technologies,
primarily driven by high-throughput genotyping and
DNA sequencing, are revolutionising our ability to resolve
those remaining rare diseases which have not proved
tractable using classical genetic approaches and to address
meaningfully the heritable basis of common diseases in
which immune dysregulation plays a significant role [4,5].
Moreover, we now have the tools to interrogate normal
variation between healthy individuals to assess genetic
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on cell or tissue type and environmental factors.
Genomic approaches such as GWAS have allowed pre-
viously unrecognised genomic loci, genes, proteins, and
pathways involved in a particular process to be identified.
In this context GWAS have been a notable success, partic-
ularly in terms of autoimmune and other immune-related
conditions (Box 2, Figures 1 and 3), as exemplified by
studies discussed here that highlight not only novel
insights into disease pathogenesis but also the previously
unappreciated extent of overlap between diseases in terms
of associated loci [6,7]. However, considerable challenges
remain: although GWAS have provided a genomic route-
map of likely functional loci, in most instances we do not
know what the specific causal functional variants are,
which genes are being modulated, and how they relate
to disease.
Another layer of complexity is added by the fact that, in
most instances, non-coding sequence variants have been
causally implicated by GWAS, and immune dysfunction is
no exception to this trend. In these cases, expression
quantitative-trait mapping offers an important comple-
mentary approach for resolving regulatory genetic var-
iants and the genes affected. Interestingly, these studies
have revealed significant overlap between disease and
expression-associated genetic markers [8–10], and have
pointed to commonalities between diseases historically
considered unrelated. The extent of sequence level and
structural genomic diversity revealed by sequencing stud-
ies such as the 1000 Genomes Project [11], combined with
the extraordinary complexity of the genomic regulatory
landscape being revealed by advances in functional geno-
mics such as the ENCODE Project [12,13], highlight the
challenges and opportunities that lie ahead in identifying
functionally important genetic variation in non-coding
regions and its consequences for immune function.
In addition to understanding genetic variation in both
coding and regulatory regions, progress in understanding
disease pathogenesis and opportunities for treatment of
immune diseases will require the integration of genetic
and environmental risk in a much more holistic way than
has been achieved to date, taking into account epigenetic
processes and context-specific effects in immune function
[12,14,15]. In this review I highlight some of the insights
gained from applying genomic approaches to Mendelian
immune diseases and to polygenic autoimmune disorders,
explore the role of regulatory and structural variants in the
MHC and genome-wide, and suggest important directions
for future research.0.1016/j.tig.2012.10.006 Trends in Genetics, February 2013, Vol. 29, No. 2
Box 1. Overview of aspects of immune system function and
disease
The immune response can be traditionally divided into innate and
adaptive immunity (Figure 1), although overlap exists. The evolu-
tionarily ancient innate immune response provides a very rapid
defence mechanism (within minutes of infection) involving inflam-
mation, complement activation, phagocytosis, and destruction of
pathogens. The innate immune response is critically dependent on
pattern-recognition receptors (PRRs), such as Toll-like receptors
(TLRs) found on the cell surface or endosomes in effector cells
(including macrophages, neutrophils, and dendritic cells), that
recognise pathogen-associated molecular patterns (PAMPs) typi-
cally located on the surface of pathogen cells. The resulting gene
activation leads to cytokine and chemokine release and generation
of an inflammatory response.
By contrast, the adaptive immune response typically takes days to
become effective following first exposure, and involves B and T
lymphocytes with recognition of antigens and the generation of a
specific antibody-mediated (humoral) response together with cell-
mediated immunity involving, for example, T helper cells and
cytotoxic T cells. The humoral response will eliminate pathogens
and allows for generation of immunological memory. Antibodies
may act, for example, to neutralise bacterial toxins, opsonise
bacteria to target them (for example promoting phagocytosis), or
result in complement activation.
Antigens are presented by specific molecules encoded by the
major histocompatibility complex (MHC) on chromosome 6p21 and
involves specialised antigen-presenting cells including dendritic
cells, monocytes, and B cells. This may involve the endogenous
pathway (for example in viral infection), in which the peptide is
loaded onto MHC class I molecules and presented to CD8+ cytotoxic
T cells (Figure 1), or the exogenous pathway (bacteria, parasites)
and loading onto an MHC class II molecule and presentation to a
CD4+ T helper cell. The MHC is a highly gene-dense and
polymorphic region which includes the classical human leukocyte
antigen (HLA) class I and class II genes and shows remarkably
strong disease associations with a broad range of autoimmune,
infectious, and inflammatory diseases.
Autoimmune diseases involve a failure of self-tolerance and an
immune response to a self-antigen with the presence of self-reactive
CD4+ T lymphocytes and typically autoantibodies. Autoimmune
diseases are often familial and include a range of common
devastating conditions that may be organ-specific (e.g., type I
diabetes, multiple sclerosis, autoimmune thyroid disease, coeliac
disease, Crohn’s disease, ulcerative colitis, psoriasis, rheumatoid
arthritis) or systemic (e.g., systemic lupus erythematosus, derma-
tomyositis, scleroderma).
Review Trends in Genetics February 2013, Vol. 29, No. 2Application of genomic approaches to primary
immunodeficiency disorders
Historically, genetic investigation of rare Mendelian pri-
mary immunodeficiency disorders has been highly infor-
mative in understanding immune function [16], and
examples are illustrated in Figures 1 and 2. Such ‘experi-
ments of nature’ [17] proved in many cases to be tractable
to classical linkage analysis and association mapping.
Characterised traits range from severe combined immu-
nodeficiency syndromes, with specific defects in cellular
and humoral immunity, to defects in innate immunity such
as impaired TLR signalling (Box 1, Figure 2). Elucidation
of the bare lymphocyte syndromes for example was ex-
tremely important in resolving mechanisms of immune
regulation, notably the nature and role of the HLA class
II master regulator CIITA [18] and the RFX complex in
regulating class II gene promoters [19].
Primary immunodeficiencies characterised by signifi-
cant autoimmune dysfunction have provided importantinsights into central tolerance from study of the rare
disease autoimmune polyendocrine syndrome 1 (APS1)
and the identification of mutations in the autoimmune
regulator (AIRE), a transcription factor regulating expres-
sion of self antigens in the thymus [20]; and of peripheral
tolerance through definition of the role of the transcription
factor FOXP3, mutation of which causes IPEX (immune
dysregulation polyendocrinopath enteropathy X-linked)
and results in autoimmunity through dysfunction of regu-
latory T cells [21,22]. Rare single-gene defects modulating
B cell function and antibody production that result in
immunodeficiency have been similarly informative
(Figure 2). Examples range from investigation of X-linked
agammaglobulinaemia, revealing the essential role for the
tyrosine kinase BTK in B cell receptor signalling and
maturation, to mutations underlying X-linked hyper IgM
syndrome demonstrating that CD40 is essential for class
switching and development of B cell memory [2].
Despite these successes, the identification of causative
genes for some primary immunodeficiencies through classi-
cal approaches has been hampered by the small numbers of
informative cases. Recent developments in genomic tech-
nology such aswhole-exome sequencing (WES) have opened
the door to resolving these rare instances and promise to
advance thisfieldsignificantly.Thisapproachhashighlight-
ed how both loss-of-function and gain-of-function alleles of
STAT1 (akey transcription factor involved in IFNsignalling
and susceptibility to mycobacterial and viral infection) may
perturb normal immune function, leading to clear disease
phenotypes [17], in this case, chronic mucocutaneous can-
didiasis (CMC), a persistent or recurrent infection with
Candida albicans involving the nails, skin, oral, or genital
mucosa [23]. Although a variety of genetic aetiologies have
been identified, here the cause of autosomal dominant CMC
was specifically investigated. The strategic approach of
using WES to analyse a small number of individuals and
then sequence the coding region of the implicated gene in a
largernumberof individualswashighlyproductive.Overall,
36 patients from 20 kindreds were found to be heterozygous
for one of 12 identified mutations involving the coiled-coil
domainofSTAT1 [23]. Theworkalso illustratesa significant
advantage of studying immune traits, namely that function-
al characterisation is relatively tractable given that most of
the relevant cell types and tissues are accessible. In the
STAT1 study a clear role for the identified gain-of-function
alleles was found in terms of impaired IL-17 immunity [23].
Although the cost ofWES and whole-genome sequencing
is decreasing, it remains a less common genomic approach
than GWAS. The rarity of primary immunodeficiency dis-
orders makes it challenging, and in some instances impos-
sible, to identify sufficient cases for the GWAS to be
adequately powered because this approach requires large
numbers of cases and controls to test for association using a
genome-widepanel of geneticmarkers.Nevertheless, for the
most common immune-deficiency disorders, common vari-
able immunodeficiency (CVID) and selective IgA deficiency,
such studies have recently been performed. In the case of
CVID, a GWAS involving 363 patients confirmed the role of
the MHC, but also implicated other loci such as the disin-
tegrin and metalloprotease (ADAM) genes as well as many
rare structural variants (insertions and deletions) involving75
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Figure 1. Overview of key mediators of innate and adaptive immunity, development, and signalling. This is presented to provide context for genetic variants implicated in
different Mendelian diseases with immune phenotypes (indicated by red filled circles numbered from 1 to 30), and common autoimmune diseases (blue filled circles
numbered from 1 to 21). These numbers correspond to the diseases described in Figures 2 and 3. (a) Development of the myeloid and lymphoid lineages is shown together
with key cell types involved in innate and adaptive immunity. (b) The role of an antigen-presenting cell (illustrated here for a dendritic cell) is shown, including antigen
presentation via the endogenous pathway (MHC class I molecules) or the exogenous pathway (MHC class II molecules). The MHC gene locus is shown in terms of the
classical class I and class II regions, with the intervening class III region. (c) Toll-like receptor signalling is a key component of the innate immune response involved in
pathogen recognition (Box 1). (d) IL-12/IL-23 receptors and the JAK–STAT signalling pathways are central to the cytokine cascade and inflammatory response together with
modulation/expansion of Th17 cells. Genetic variation in genes encoding different proteins in these pathways has been associated with autoimmunity by recent GWAS
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Review Trends in Genetics February 2013, Vol. 29, No. 2for example ORC4L, a gene important for initiation of DNA
replication that was previously implicated in B cell lympho-
proliferative disorders [24]. The genetic basis of CVID
remainsunresolved [2], but it ishoped that through improved
clinical phenotyping [25] and genomic approaches the cur-
rently heterogeneous syndrome of CVID may be resolved
into distinct disorders which will aid in the development of
more targeted therapies and improved clinical care.
A recent similarly sized GWAS investigating IgA defi-
ciency also confirmed the previous MHC class II associa-
tion with this disease [26]. Subsequent fine mapping and
imputation of HLA type resolved the primary association
signal toHLA-DQB1*02 [27], which is also associated with
type 1 diabetes (T1D) and coeliac disease. Intriguingly, the
GWAS demonstrated evidence of an additional non-MHC
association involving two loci previously implicated in
autoimmune disease [26]. These included IFIH1, which
encodes an interferon-inducible RNA helicase important in
response to viral infections and implicated by GWAS in
psoriasis [28] and in T1D [29]. Interestingly, other rare
variants of IFIH1 were also subsequently found to show
independent association to T1D [30]). Similarly, the second
locus, CLEC16A, which encodes a member of the C-type
lectin domain family, is also associated with T1D, multiple
sclerosis (MS), systemic lupus erythematosus, and rheu-
matoid arthritis (RA) [31], suggesting some overlap in
disease pathogenesis [26].
GWAS generate overlapping roadmaps for
understanding autoimmunity
The associated loci shared between IgA deficiency and
other immune diseases reflects a general trend that has
been uncovered through GWAS, particularly of autoim-
mune diseases (Box 2), namely the overlap between the
pathways and mechanisms involved in immune-related
diseases [32]. In a recent analysis, among 107 independent
non-MHC single nucleotide polymorphism (SNP) markers
associated at genome-wide significance across seven com-
mon autoimmune diseases, 44% associated with at least
two diseases [7]. Intriguingly, in 8% of instances the effects
were shared but in an opposite direction, with increased
risk in some diseases and protection in others. This is seen
for example with PTPN22 R620W; it is associated with
increased risk of RA, thyroid disease and T1D, protection
for Crohn’s disease, and no effect on MS [6]. Sharing was
also notable in associations involving cytokine signalling,
pathways involved in B and T cell activation, innate im-
munity, and response to pathogens [6]. These shared pat-
terns may provide insights into common mechanisms and
unexpected overlaps in disease pathogenesis.
One outcome of identifying these shared associations
is the potential to treat diseases with drugs previously
approved for seemingly unrelated diseases (drug reposi-
tioning). Indeed, it has been found that genes currently
implicated by GWAS are significantly more likely to
be ‘druggable’ by small molecules (21%), or potentiallyimplicating dysregulation of IL-12 signalling (Th1 cells) and IL-23 signalling (Th17 cells
kinase; IL-1Rs, interleukin-1 receptors; IRAK, IL-1R-associated kinase; IRF, interferon reg
myeloid differentiation primary-response protein 88; NEMO, NF-kB essential modulato
TCR, T cell receptor; Tfh, follicular helper T cell; Th, T helper cell; TLR, Toll-like receptor;
regulatory T cell; TYK, tyrosine kinase.modulated by ‘biopharmaceuticals’ (therapeutic antibo-
dies/protein therapeutics) (47%), than those derived from
considering the whole genome (17% and 38% respectively)
[33]. One example of a candidate drug that could be repur-
posed for Crohn’s disease is an existing monoclonal anti-
body against TNFSF11 (currently used for treating
osteoporosis and bone cancer) based on the reported GWAS
signal for that disease with TNFRSF11 [34].
The MHC: still challenging 40 years on
When considering the role of genetic variation in the
immune system, the highly polymorphic MHC locus on
chromosome 6p21 is sometimes viewed as being too com-
plex and difficult to resolve, but this region of the genome is
undoubtedly the elephant in the room that refuses to go
away. GWAS have underlined what was already known
from associations based on serological testing in the early
1970s, namely that the predominant genetic risk for auto-
immune disease resides in the MHC, together with asso-
ciations for infectious and inflammatory diseases as well as
traits such as cancer and drug hypersensitivity [35]. It
remains most likely that current autoimmune-disease risk
alleles reflect past selective pressures on populations ex-
posed to an environment rich in severe infectious diseases
[35]. Infectious disease is important in driving polymor-
phisms [36], and there is evidence of positive selection
involving coding variants altering the peptide binding
grooves of MHC molecules. Selection is also evident in
non-MHC GWAS loci such as IL12A, IL18RAP, and
SH2B3 in the context of coeliac disease [37]. The extraor-
dinary degree of polymorphism in the MHC and extensive
linkage disequilibrium have made fine-mapping of disease
associations challenging [35,38]. Indeed current genomic
technologies such as whole-genome sequencing and RNA
sequencing are currently of limited utility in the MHC due
to difficulties such as read mapping bias and reliability of
variant calling. However, these difficulties should be alle-
viated as sequencing read lengths increase as well as
through de novo sequence assembly [39]. A major success
in applying genomicmethods to understanding theMHC is
SNP genotyping to establish HLA type [40,41]. This has
been recently shown to be highly accurate for imputing
HLA type to four-digit resolution for most classical alleles
[40], and may replace conventional serological testing.
The majority of autoimmune-disease associations are
thought to arise completely or in part from structural
variants involving HLA class I and II molecules, acting
in conjunction with a variety of known and unknown
germline and somatic genetic variants, epigenetic mecha-
nisms, and specific environmental triggers to modulate
tolerance (for example resulting in a permissive environ-
ment for T cells recognising self antigens [42]). The combi-
nation of these factors cumulatively results in a specific
disease phenotype. A recent study investigating structural
variants in patients with RA demonstrated the power of
using multiple large GWAS cohorts, imputation of HLA) [6]. Abbreviations: IKK, inhibitor of k light polypeptide gene enhancer in B cells
ulatory factor; JAK, Janus kinase; MHC, major histocompatibility complex; MyD88,
r; NK cell, natural killer cell; STAT, signal transducer and activator of transcription;
TRAF, TNF receptor-associated factor; TRAM, TRIF-related adaptor molecules; Treg,
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Figure 2. Examples of Mendelian traits involving immune defects. Red filled numbered circles correspond to those shown in the overview of the immune system (Figure 1).
The implicated gene (given in italics) and chromosomal position are shown together with the associated phenotype (grey shaded box). Note that the genetic variants
involved range from point mutations (single-nucleotide variants) to large structural variants. Full descriptions of all traits are available at the Online Mendelian Inheritance
in Man (OMIM) database (http://omim.org/). For the severe combined immunodeficiency (SCID) syndromes shown (numbered circles 1–7) these can be classified into T cell
negative, B cell negative, NK cell negative type (T–B–NK–) (OMIM #102700) (circle 2); T–B–NK+ (OMIM #601457) (circle 1); T–B+NK– (OMIM #300400, #600802, #601457) (circles
3,4,7); T–B+NK+ (OMIM #608971) (circles 5,6). DiGeorge syndrome (OMIM #188400) (circle 8) due to deletion at chr22q11 includes a T cell deficit due to thymic hypoplasia. X-
linked agammaglobulinemia (XLA) (OMIM #300755) (circle 9) due to mutation involving the BTK gene is an immunodeficiency syndrome characterised by failure to produce
mature B cells and of Ig heavy-chain rearrangement. Autoimmune polyendocrine syndrome (APS) (OMIM #240300) (circle 10) due to mutations in AIRE is characterised by
two of three of Addison disease (adrenal insufficiency), hypoparathyroidism, and chronic mucocutaneous candidiasis, and arises due to failure of central immune tolerance.
CD8 deficiency (OMIM #608957) (circle 11) is characterised by the absence of CD8+ T cells. Autoimmune lymphoproliferative syndrome (ALPS) (OMIM #601859) manifests
with autoreactive lymphocytes due to disordered apoptosis, either ALPS type 1A (circle 12) due to mutation in the FAS gene, or ALPS type 1B (circle 13) involving the FAS
ligand (FASL) gene. X-linked lymphoproliferative syndrome (XLP) (OMIM #308240), due to mutation in SH2D1A (circle 14), results in severe immunodysregulation, notably
in the context of viral infection. IPEX (immunodysregulation, polyendocrinopathy, and enteropathy X-linked syndrome) (OMIM #304790) (circle 15) is an X-linked disorder
associated with severe diarrhoea, T1D, and dermatitis due to mutation in FOXP3. Hyper IgM syndrome 1 (HIGM1) (OMIM #308230) (circle 16) due to mutation in CD40LG.
Bare lymphocyte syndrome type I (OMIM #604571) (circle 17) involves failure of expression of HLA class I genes due to mutation in TAP1, TAP2, or TABP genes, and has a
relatively mild phenotype with chronic bacterial infections. By contrast, bare lymphocyte syndrome type II (OMIM ##209920) is associated with severe combined
immunodeficiency with different complementation groups, group A (mutation in CIITA) (circle 18), group B (mutation in RFXANK) (circle 19), group C (mutation in RFX5)
(circle 20), and group D (mutation in RFXAP) (circle 21). Mutations involving TLR signalling [85] are illustrated (numbered circles 24–29). Mutations involving the canonical
pathway include X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (XDA-ID) (OMIM #300291) due to hypomorphic mutations in NEMO (circle 22),
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Box 2. Autoimmune disorders and GWAS
GWAS have been highly informative in autoimmune diseases,
uncovering associations with many different genomic loci beyond
the MHC and providing new insights into pathogenesis (Figures 1 and
3). Over 200 genomic loci have been implicated in autoimmune
disease [6]. These have been extensively reviewed [6,42,71], and a
very useful source of current information about these data is the
NHGRI Catalogue of Published Genome-Wide Association Studies
(www.genome.gov/gwastudies/).
Autoimmune diseases such as Crohn’s disease have been high-
lighted as significant GWAS success stories in which new pathways
and potential drug targets have been resolved. This includes genes
encoding components of cytokine signalling, notably IL2RA and
IL23R, as well as of innate immunity including autophagy (for
example ATG16L1) and NOD2 (which acts as a sensor of bacterial
peptidoglycan), although the role of NOD2 was identified prior to
GWAS [72]. It is striking that genetic variation involving genes at
diverse genomic locations, but encoding proteins involved in a given
pathway, should be associated with a particular immune phenotype
or related phenotypes; for example, strong associations have been
recognised between IL-23/IL-12 signalling pathways and several
autoimmune diseases including inflammatory bowel disease, psor-
iasis, and primary biliary cirrhosis [6,73] (Figures 1 and 3). In some
instances, such as for PTPN22 (which was initially identified by a
candidate gene approach [74]), the functional risk allele has been
established – in this case a nonsynonymous variant (rs2476601,
R620W) disrupting binding between the intracellular phosphatase
encoded by PTPN22 and the kinase Csk, altering T and B cell
responsiveness to receptor stimulation. In the vast majority of cases
the modulated gene and functional variant remains unresolved and is
likely in many instances to involve functional regulatory elements in
non-coding DNA [4,12,75].
The human microbiome (microbes that live in and on our bodies) is
increasingly recognised as a critical modulator of the host immune
system and is the subject of intensive research [76]. The role of
genetic variation in this relationship is likely to be highly significant,
as illustrated by recent work involving a GWAS locus for rheumatoid
arthritis, ulcerative colitis, and coeliac disease at TNFRSF14 (HVEM)
[77]. The gene was found to encode a member of the tumor necrosis
factor receptor superfamily that is an important orchestrator of
mucosal immunity and defence against pathogenic bacteria [77].
A recent example of how GWAS signals may be informative for
understanding disease pathogenesis and use of therapeutics comes
from work on a highly significant GWAS signal for multiple sclerosis,
localising to TNFRSF1A with a modest magnitude of effect [odds ratio
for risk allele = 1.12 (1.11–1.14)]; further study revealed a functional
association with the production of a novel stable soluble form of the
encoded TNF receptor 1 (TNFR1) [78]. This variant occurs when the
risk allele is alternatively spliced to produce a transcript lacking exon 6
and a protein capable of antagonizing TNF. This is consistent with the
worsening of multiple sclerosis seen with anti-TNF treatment, which
is in contrast to other autoimmune diseases, and it was striking that
this SNP has not been associated with other autoimmune conditions.
Review Trends in Genetics February 2013, Vol. 29, No. 2type, and sophisticated conditional analysis [43]. This
study significantly advanced the longstanding shared-epi-
tope hypothesis for susceptibility to RA involving consen-
sus amino acid sequences spanning positions 70–74 in the
b1 subunit of HLA-DR, which were implicated but could
not fully explain the disease association. Analysis of six
GWAS cohorts involving 19 992 individuals, including
5018 cases of anti-citrullinated peptide-positive RA, at
the level of SNP, haplotype, and HLA type revealed the
strongest association was with rs17878703, corresponding
to amino acid position 11 of DRb1, with further indepen-
dent signals revealed for variants at amino acids 71 and 74,
all located centrally in the peptide-binding groove [43].
Serial conditional analysis revealed further independent
effects for amino acid position 9 in HLA-B and in HLA-
DPb1. This elegant work is undoubtedly a further signifi-
cant advance but will require careful functional character-
isation to establish causality and a clear understanding of
mechanism.
Recent GWAS have also underlined the role of interac-
tions involving the MHC, for example of HLA-B27 and
genetic variation in ERAP1 [44], a gene encoding an endo-
plasmic reticulum aminopeptidase involved in peptide
trimming before HLA class I presentation. The situation
is complex, with other new functional evidence linking
pathogenic HLA-B27 homodimers with binding to natural
killer and related immunoreceptors such as KIR3DL2 [45].
KIR receptors are mainly expressed on natural killer cells
and are critical to maintaining tolerance, binding HLA
class I ligands on target cells. Indeed the KIR gene locus
is, similarly to the MHC, extremely polymorphic. Fora critical subunit of the inhibitory IKK complex, resulting in defective NF-kB signalling
MYD88 deficiency (OMIM #612260) (circle 24), involving genes encoding adaptors recrui
recessive conditions and pyogenic bacterial infections; and ectodermal dysplasia, anhid
NFKB1A and altered IkBa activity. Mutations in the alternative TLR pathway, and that are
encephalitis, include TLR3 (OMIM #613002) (circle 26), UNC93B (OMIM #610551) (circleinfections such as HIV-1, analysis of both MHC and KIR
diversity has proven highly informative, notably forHLA-B
alleles and variants involving KIR3DL1 and KIR3DS1,
inhibitory and activating receptors respectively, and re-
cent work also implicates copy-number variation [46]. The
KIR locus is currently not well captured by GWAS geno-
typing arrays but is the subject of active research interest.
MHC interactions are also being highlighted by recent
expression quantitative-trait mapping studies in which
possession of specific genetic variants in this region show
association with differential expression of genes elsewhere
in the genome. These include a reported GWAS SNP for
ulcerative colitis in the MHC class II region associated
with expression of AOAH, a gene encoding the enzyme
acyloxyacyl hydrolase which plays a key role in the inflam-
matory response to Gram-negative bacteria located on
chromosome 7p14 [47]. This association was shown to be
cell type-specific and resolved to HLA class II alleles HLA-
DRB1*04, HLA-DRB1*07, and HLA-DRB1*09 [48]. In-
triguingly, these alleles associated with reduced AOAH
expression were found to have a second monocyte-specific
trans association, in this case to higher expression of
ARHGAP24, which encodes a negative regulator of Rho
GTPase-activating protein, suggesting new candidates to
investigate when considering the known autoimmune-dis-
ease associations of these alleles [49].
The hypothesis that regulatory variants play a role in
the many observed disease associations for the MHC is
consistent with evidence from characterisation of specific
loci, such as HLA-C, where local association was found
with differential gene expression that involved a geneticand susceptibility to infection; IRAK4 deficiency (OMIM #607676) (circle 23) and
ted during TLR signalling in response to microbial products, resulting in autosomal
rotic, with T cell immunodeficiency (OMIM #164008) (circle 25) due to mutation in
associated with susceptibility to viral infections such as herpes simplex virus (HSV)
27), TRAF3 (circle 28) and TRIF (circle 29).
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Figure 3. Examples of common autoimmune diseases where loci have been reported by GWAS. Blue filled numbered circles correspond to those shown in the overview of the
immune system (Figure 1). This is not an exhaustive list and illustrates the overlap seen at many associated loci for different autoimmune diseases and how genes encoding
different components of pathways may be associated with a given disease using data from [6] and the National Human Genome Research Institute (NHGRI) Catalogue of
Published Genome-Wide Association Studies (www.genome.gov/gwastudies/) where full details can be found. It should also be noted that, in the majority of cases, the genes
listed are candidates based on the genomic locus that was associated, and causality has not been established except in a small number of instances. Abbreviations: alopecia,
alopecia areata; AS, ankylosing spondylitis; CD, Crohn’s disease; coeliac, coeliac disease; Graves, Grave’s disease;MG, myasthenia gravis; MS, multiple sclerosis; PBC, primary
biliary cirrhosis; Ps, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis.
Review Trends in Genetics February 2013, Vol. 29, No. 2variant associated with HIV-1 control [50]. Recent work
suggests this associationmay arise from a linked variant in
the 30-UTR and differential binding of a microRNA [51].
More generally, expression quantitative-trait mapping has
demonstrated many strong associations with this region of
the genome [38]. Care is needed, however, because the
polymorphic nature inherent to the MHC risks confound-
ing results through differential hybridization of probes on
conventional microarray platforms in the presence of a
variant allele. Recent work using a custom MHC array
has interrogated gene expression using lymphoblastoid
cell lines homozygous for specific disease risk haplotypes
[52]. This array included alternative allele probes at the
site of a given single-nucleotide variant together with a
tiling path design able to quantify expression specific to
both sense and antisense strands that included intergenic
regions and for the class III region as well as known and
predicted splice junctions. This revealed that haplotype-
specific transcription was common, comprising up to 11.1%
of transcriptionally active regions and involving 96 genes
[52]. Haplotypic differences were noted to often involve
alternative splicing, which was significantly enriched in80the MHC. Consistent with these results, expression quan-
titative-trait mapping resolved cis-acting associations.
This work provides several candidate genes for further
study to assess the contribution of regulatory variants to
MHC disease associations.
Expression quantitative-trait mapping and immune
phenotypes
Expression quantitative-trait mapping in humans has been
of growing interest following the recognition that gene
expression is a heritable trait showing significant variation
within and between populations that can be resolved based
on linkage or, more recently, association to specific SNP
markers [53]. Following the successful use of ‘genetical
genomics’ in model organisms [54], this approach now
provides a powerful tool for mapping regulatory genetic
variants that is complimentary to, and can be highly infor-
mative for, GWAS for disease traits. One of the first studies
adopting this approach studied lymphoblastoid cell lines,
established from a cohort of children with asthma, which
found that expression-associatedSNPs (eSNPs)modulating
ORMDL3 were also the most significant GWAS SNPs for
Box 3. Epigenetics and immune cell development,
differentiation, and function
Dynamic epigenetic marks are critical in determining whether CD4+
T helper cells differentiate down a Th1 or Th2 pathway on leaving
the thymus, as seen for example by gain of active or repressive
histone modifications/DNA methylation at the IFNg and Th2
cytokine gene locus [65]. In terms of B cell differentiation, directional
DNA methylation changes play an important role [79], as illustrated
by changes in the promoter of the developmentally regulated gene
CD79A [80]. Epigenetic mechanisms are also critical to assembly of
B and T cell receptors through V(D)J rearrangement, and changes in
DNA methylation, histone modifications, chromatin accessibility,
and structure are important in controlling accessibility of recombi-
nation signal sequences [81]. Epigenetics is also thought to be
important in immunological memory, and recent evidence from
work involving Candida albicans demonstrated the concept of
training of the immune system through epigenetic modifications
(in this case stable changes in histone trimethylation at H3K4),
leading to protection against reinfection [82].
Review Trends in Genetics February 2013, Vol. 29, No. 2asthma [55]. Current work suggests the association with
expression may be tissue specific [56].
In terms of immune phenotypes, recent expression quan-
titative-trait mapping studies have proved to be highly
informative, notably for autoimmune diseases [48,57,58].
Analysis of primary immune cell types has demonstrated a
high level of cellular specificity in eSNPs, underlining the
importance of context specificity for regulatory variants. A
recent studyof paired samples ofmonocytes andB cells from
healthy volunteers revealed the majority of associations
were cell type-specific, notably among trans-associations
[48]. Moreover, the analysis highlighted how directional
effects occur for genes similarly expressed in both cell types
in which an eSNP may show opposite directions of associa-
tion, such as for the cell surface receptor CD62L important
in the local inflammatory response [48]. Several cell type-
specific trans-associations were resolved, including a B cell-
specific association involving 12q13.2, a major autoimmune
GWAS locus for several traits including T1D [48]. This
showed that, in addition to the previously investigated
and controversial local associations with expression of
RPS26 [59], trans-association is present for IP6K2 and a
transcriptmapping 50 toCDKN1A, which suggests a role for
p53 mediated apoptosis and cell-cycle regulation. Overall,
49.4% of traits in the National Human Genome Research
Institute (NHGRI) Catalog of Published Genome-Wide As-
sociation Studies (17.3% of reported GWAS SNPs) were
associated with one or more eSNPs in this dataset, with
4.6% ofGWASSNPs showing associationwith expression of
different genes in a cell type-specific manner [48]. GWAS
hits for systemic lupus erythematosus, for example, mainly
involvedB cell-specific eSNPs, whereas for ulcerative colitis
the associations were mainly monocyte-specific, consistent
with the contrasting aetiologies of these two diseases
involving adaptive and innate immunity.
Haematological traits relevant to immunity, such as
white-cell count and abundance of specific cell subtypes,
have a heritable component contributing to observed vari-
ation. Among individuals of African ancestry for example,
lower white-cell counts are observed, and this was found to
be associated with a specific null regulatory variant of
DARC, a variant that confers a strong selective advantage
in malaria [60]. Recent GWAS have resolved several asso-
ciations [61,62], including variants at chromosome 17q21
near CSF3 that show association with neutrophil and total
white blood cell count [61,63,64]. This is interesting given
the disease association of this locus with RA and asthma,
and the clinical utility of granulocyte colony stimulating
factor (encoded by CSF3) in treating neutropenia. Other
striking associations (reviewed in [62]) include variants
at chromosome 2q31 near ITGA4 with monocyte count.
ITGA4 encodes a component of integrin important in
white-cell tissue migration.
Epigenetic variation, functional genomics, and the
immune system
Epigenetic mechanisms modulating gene expression, such
as DNA methylation, histone modifications, and non-cod-
ingRNAs, play a critical role in the immune system [15,65].
This is manifest in the complex and essential regulation of
immune-cell identity and function during development anddifferentiation to generate multiple cell lineages, with
remodelling of the epigenome acting to restrict or promote
gene expression and determine cell fate (Box 3). Epigenetic
regulation has been found to be highly dynamic and re-
sponsive, providing an important interface with the envi-
ronment and memory of past exposures. Several
environmental risk factors for autoimmune disease have
been linked through epigenetics including cigarette smok-
ing, infections such as Epstein–Barr virus, exposure to
reproductive hormones, and vitamin D deficiency [66].
Gene–environment interactions have been resolved for
example in RA between cigarette smoking and HLA-
DRB1 risk alleles [67] together with other gene loci such
as PTPN22 [68]. Epigenomic approaches can be informa-
tive for specific environmental risk factors such as vitamin
D deficiency. The vitamin D receptor (VDR) is a ligand-
activated transcription factor, and recent analysis of VDR
genome-wide occupancy using ChIP-seq revealed that loci
associated by GWAS in several autoimmune conditions
including IRF8 (associated with MS) and PTPN2 (Crohn’s
disease and T1D) were bound by VDR [69]. For specific
disease risk alleles in the MHC, there is evidence suggest-
ing allele-specific recruitment of VDR at the promoter of
HLA-DRB1, which illustrates how environmental and ge-
netic risk factors may be related [70].
Genomic approaches such as GWAS and WES have
proven very powerful in defining the extent and nature
of genetic variation in the context of immune function and
disease. However, considerable challenges remain, not
least in establishing causal functional variants (Box 4).
The design of functional studies requires careful consider-
ation of context-specific effects, with increasing emphasis
on analysis of primary cells in a disease setting where
complementary functional genomic, epigenomic, and
proteomic approaches can be applied together with immu-
nological assays and testing of hypotheses in model organ-
isms. Interpretation will be facilitated by adoption of a
more systems-based approach and the analysis and inte-
gration of genetic, epigenetic, and environmental modula-
tors of disease. Expression quantitative-trait mapping has
proven a valuable tool to resolve regulatory variants, and
future studies in specific contexts should be very helpful in81
Box 4. Challenges to using genomic approaches to
understand immune function, and future directions
GWAS have achieved considerable success in resolving association
with common traits, notably in the context of autoimmune disorders
as described. There are of course caveats to such enthusiasm,
notably in terms of the modest magnitude of effect and overall small
proportion of estimated heritable risk explained, the challenges of
moving from associated locus to causal functional variant, and
indeed even implicating specific modulated genes based on
associated SNP markers [12,83]. For whole-exome and whole-
genome sequencing datasets in which rare variants are sought to
resolve the basis of immune traits such as those showing Mendelian
inheritance, the analysis of such datasets also remains challenging,
and the tools available and optimal strategies for experimental
design are incompletely developed [84]. Moreover, it is important to
note that combining the use of technologies to resolve sequence
and structural genomic variation with careful immunological studies
of function to establish causal relationships remains paramount to
successful implementation of current genomic approaches and the
identification of causal functional variants. It is also important to
note that our ability to study and quantify genomic variation is very
much focused on DNA sequence variation, and we are currently not
well-equipped to dissect either the more repetitive regions of the
genome or a significant proportion of structural genomic variants.
Ongoing and future research should provide new approaches to
interrogate such regions and variants in the context of the immune
system. Similarly, the technologies for epigenomic profiling, for
example of DNA methylation at genome-wide resolution, are not yet
sufficiently developed for widespread adoption. Finally, the often
enigmatic nature of the MHC seems likely to continue to keep its
secrets for some time more because the difficulties of applying high-
throughput sequencing to this region of the genome remain very
significant due to the high level of sequence and structural
polymorphism found in this region.
Review Trends in Genetics February 2013, Vol. 29, No. 2defining the extent and nature of genetic associations, in
particular those involving trans-acting variants. The use of
RNA sequencing should further increase the informative-
ness of such studies, identifying alternatively spliced tran-
scripts and non-coding RNAs as well as allele-specific
expression involved in immune dysfunction.
Concluding remarks
Genetic variation plays a fundamental role in modulating
the development and effective functioning of the immune
system. Recent work has illustrated how we can use geno-
mic and epigenomic approaches to define such variation
and understand the immune response in health and dis-
ease. This offers the promise of improved insights into
disease pathogenesis, better diagnostic accuracy, new or
repositioned therapeutics targeted to maximise benefit for
the individual, and opportunities to improve outcome. To
deliver on this will require continued excellence in basic
science and translational research spanning genetics and
immunology which takes advantage of current technologi-
cal advances and our ability to resolve ‘experiments of
nature’ seen in immune dysfunction.
Acknowledgements
Work in the laboratory of J.K. has been supported by the Wellcome Trust
(074318 and 075491/Z/04 to core facilities Wellcome Trust Centre for
Human Genetics), the European Research Council (ERC) under Eur-
opean Commission 7th Framework Programme (FP7/2007–2013)/ERC
grant agreement No. 281824, the Medical Research Council (98082), and
the National Institute for Health Research (NIHR) Oxford Biomedical
Research Centre.82References
1 Casanova, J.L. et al. (2012) Inborn errors of human JAKs and STATs.
Immunity 36, 515–528
2 Cunningham-Rundles, C. (2012) Human B cell defects in perspective.
Immunol. Res. 54, 227–232
3 van der Burg, M. et al. (2012) New frontiers of primary antibody
deficiencies. Cell. Mol. Life Sci. 69, 59–73
4 Knight, J.C. (2010) Understanding human genetic variation in the era
of high-throughput sequencing. EMBO Rep. 11, 650–652
5 Bamshad, M.J. et al. (2011) Exome sequencing as a tool for Mendelian
disease gene discovery. Nat. Rev. Genet. 12, 745–755
6 Cho, J.H. and Gregersen, P.K. (2011) Genomics and the multifactorial
nature of human autoimmune disease.N. Engl. J.Med. 365, 1612–1623
7 Cotsapas, C. et al. (2011) Pervasive sharing of genetic effects in
autoimmune disease. PLoS Genet. 7, e1002254
8 Montgomery, S.B. and Dermitzakis, E.T. (2011) From expression QTLs
to personalized transcriptomics. Nat. Rev. Genet. 12, 277–282
9 Nicolae, D.L. et al. (2010) Trait-associated SNPs are more likely to be
eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 6,
e1000888
10 Majewski, J. and Pastinen, T. (2010) The study of eQTL variations by
RNA-seq: from SNPs to phenotypes. Trends Genet. 27, 72–79
11 Durbin, R.M. et al. (2010) A map of human genome variation from
population-scale sequencing. Nature 467, 1061–1073
12 Knight, J.C. (2012) Resolving the variable genome and epigenome in
human disease. J. Intern. Med. 271, 379–391
13 Consortium, E.P. (2012) An integrated encyclopedia of DNA elements
in the human genome. Nature 489, 57–74
14 Rakyan, V.K. et al. (2011) Epigenome-wide association studies for
common human diseases. Nat. Rev. Genet. 12, 529–541
15 Fernandez-Morera, J.L. et al. (2010) Epigenetic regulation of the
immune system in health and disease. Tissue Antigens 76, 431–439
16 Notarangelo, L.D. (2010) Primary immunodeficiencies. J. Allergy Clin.
Immunol. 125, S182–S194
17 Boisson-Dupuis, S. et al. (2012) Inborn errors of human STAT1: allelic
heterogeneity governs the diversity of immunological and infectious
phenotypes. Curr. Opin. Immunol. 24, 364–378
18 de Preval, C. et al. (1985) A trans-acting class II regulatory gene
unlinked to the MHC controls expression of HLA class II genes.
Nature 318, 291–293
19 Reith, W. and Mach, B. (2001) The bare lymphocyte syndrome and the
regulation of MHC expression. Annu. Rev. Immunol. 19, 331–373
20 Metzger, T.C. and Anderson, M.S. (2011) Control of central and
peripheral tolerance by Aire. Immunol. Rev. 241, 89–103
21 Bennett, C.L. et al. (2001) The immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is
caused by mutations of FOXP3. Nat. Genet. 27, 20–21
22 Wildin, R.S. et al. (2001) X-linked neonatal diabetes mellitus,
enteropathy and endocrinopathy syndrome is the human equivalent
of mouse scurfy. Nat. Genet. 27, 18–20
23 Liu, L. et al. (2011) Gain-of-function human STAT1 mutations impair
IL-17 immunity and underlie chronic mucocutaneous candidiasis. J.
Exp. Med. 208, 1635–1648
24 Radojkovic, M. et al. (2009) Novel ORC4L gene mutation in B-cell
lymphoproliferative disorders. Am. J. Med. Sci. 338, 527–529
25 Chapel, H. (2012) Classification of primary immunodeficiency diseases
by the International Union of Immunological Societies (IUIS) Expert
Committee on Primary Immunodeficiency 2011. Clin. Exp. Immunol.
168, 58–59
26 Ferreira, R.C. et al. (2010) Association of IFIH1 and other
autoimmunity risk alleles with selective IgA deficiency. Nat. Genet.
42, 777–780
27 Ferreira, R.C. et al. (2012) High-density SNP mapping of the HLA
region identifies multiple independent susceptibility loci associated
with selective IgA deficiency. PLoS Genet. 8, e1002476
28 Strange, A. et al. (2010) A genome-wide association study identifies
new psoriasis susceptibility loci and an interaction between HLA-C
and ERAP1. Nat. Genet. 42, 985–990
29 Smyth, D.J. et al. (2006) A genome-wide association study of
nonsynonymous SNPs identifies a type 1 diabetes locus in the
interferon-induced helicase (IFIH1) region. Nat. Genet. 38, 617–619
30 Nejentsev, S. et al. (2009) Rare variants of IFIH1, a gene implicated in
antiviral responses, protect against type 1 diabetes. Science 324, 387–389
Review Trends in Genetics February 2013, Vol. 29, No. 231 Wang, N. et al. (2011) Selective IgA deficiency in autoimmune diseases.
Mol. Med. 17, 1383–1396
32 Zhernakova, A. et al. (2009) Detecting shared pathogenesis from the
shared genetics of immune-related diseases.Nat. Rev. Genet. 10, 43–55
33 Sanseau, P. et al. (2012) Use of genome-wide association studies for
drug repositioning. Nat. Biotechnol. 30, 317–320
34 Franke, A. et al. (2010) Genome-wide meta-analysis increases to 71 the
number of confirmed Crohn’s disease susceptibility loci.Nat. Genet. 42,
1118–1125
35 Trowsdale, J. (2011) The MHC, disease and selection. Immunol. Lett.
137, 1–8
36 Lederberg, J. (1999) Haldane J.B.S. (1949) on infectious disease and
evolution. Genetics 153, 1–3
37 Zhernakova, A. et al. (2010) Evolutionary and functional analysis of
celiac risk loci reveals SH2B3 as a protective factor against bacterial
infection. Am. J. Hum. Genet. 86, 970–977
38 Vandiedonck, C. and Knight, J.C. (2009) The human major
histocompatibility complex as a paradigm in genomics research.
Brief. Funct. Genomic Proteomic 8, 379–394
39 Iqbal, Z. et al. (2012) De novo assembly and genotyping of variants
using colored de Bruijn graphs. Nat. Genet. 44, 226–232
40 Leslie, S. et al. (2008) A statistical method for predicting classical HLA
alleles from SNP data. Am. J. Hum. Genet. 82, 48–56
41 Monsuur, A.J. et al. (2008) Effective detection of human leukocyte
antigen risk alleles in celiac disease using tag single nucleotide
polymorphisms. PLoS ONE 3, e2270
42 Kuchroo, V.K. et al. (2012) Dysregulation of immune homeostasis in
autoimmune diseases. Nat. Med. 18, 42–47
43 Raychaudhuri, S. et al. (2012) Five amino acids in three HLA proteins
explain most of the association between MHC and seropositive
rheumatoid arthritis. Nat. Genet. 44, 291–296
44 Evans, D.M. et al. (2011) Interaction between ERAP1 and HLA-B27 in
ankylosing spondylitis implicates peptide handling in the mechanism
for HLA-B27 in disease susceptibility. Nat. Genet. 43, 761–767
45 Payeli, S.K. et al. (2012) Inhibiting HLA-B27 homodimer-driven
immune cell inflammation in spondyloarthritis. Arthritis Rheum. 64,
3139–3149
46 Pelak, K. et al. (2011) Copy number variation of KIR genes influences
HIV-1 control. PLoS Biol. 9, e1001208
47 Silverberg, M.S. et al. (2009) Ulcerative colitis-risk loci on
chromosomes 1p36 and 12q15 found by genome-wide association
study. Nat. Genet. 41, 216–220
48 Fairfax, B.P. et al. (2012) Genetics of gene expression in primary
immune cells identifies cell type-specific master regulators and roles
of HLA alleles. Nat. Genet. 44, 502–510
49 Rioux, J.D. et al. (2009) Mapping of multiple susceptibility variants
within the MHC region for 7 immune-mediated diseases. Proc. Natl.
Acad. Sci. U.S.A. 106, 18680–18685
50 Thomas, R. et al. (2009) HLA-C cell surface expression and control of
HIV/AIDS correlate with a variant upstream of HLA-C.Nat. Genet. 41,
1290–1294
51 Kulkarni, S. et al. (2011) Differential microRNA regulation of HLA-C
expression and its association with HIV control. Nature 472, 495–498
52 Vandiedonck, C. et al. (2011) Pervasive haplotypic variation in the
spliceo-transcriptome of the human major histocompatibility complex.
Genome Res. 21, 1042–1054
53 Cookson, W. et al. (2009) Mapping complex disease traits with global
gene expression. Nat. Rev. Genet. 10, 184–194
54 Rockman, M.V. and Kruglyak, L. (2006) Genetics of global gene
expression. Nat. Rev. Genet. 7, 862–872
55 Moffatt, M.F. et al. (2007) Genetic variants regulating ORMDL3
expression contribute to the risk of childhood asthma. Nature 448,
470–473
56 Fu, J. et al. (2012) Unraveling the regulatory mechanisms underlying
tissue-dependent genetic variation of gene expression. PLoS Genet. 8,
e1002431
57 Fehrmann, R.S. et al. (2011) Trans-eQTLs reveal that independent
genetic variants associated with a complex phenotype converge on
intermediate genes, with a major role for the HLA. PLoS Genet. 7,
e1002197
58 Nica, A.C. et al. (2011) The architecture of gene regulatory variation
across multiple human tissues: the MuTHER study. PLoS Genet. 7,
e100200359 Plagnol, V. et al. (2009) Statistical independence of the colocalized
association signals for type 1 diabetes and RPS26 gene expression on
chromosome 12q13. Biostatistics 10, 327–334
60 Reich, D. et al. (2009) Reduced neutrophil count in people of African
descent is due to a regulatory variant in the Duffy antigen receptor for
chemokines gene. PLoS Genet. 5, e1000360
61 Nalls, M.A. et al. (2011) Multiple loci are associated with white blood
cell phenotypes. PLoS Genet. 7, e1002113
62 Okada, Y. and Kamatani, Y. (2012) Common genetic factors for
hematological traits in humans. J. Hum. Genet. 57, 161–169
63 Okada, Y. et al. (2010) Common variations in PSMD3-CSF3 and
PLCB4 are associated with neutrophil count. Hum. Mol. Genet. 19,
2079–2085
64 Kamatani, Y. et al. (2010) Genome-wide association study of
hematological and biochemical traits in a Japanese population. Nat.
Genet. 42, 210–215
65 Suarez-Alvarez, B. et al. (2012) DNA methylation: a promising
landscape for immune system-related diseases. Trends Genet. 28,
506–514
66 Costenbader, K.H. et al. (2012) Genes, epigenetic regulation and
environmental factors: which is the most relevant in developing
autoimmune diseases? Autoimmun. Rev. 11, 604–609
67 Karlson, E.W. et al. (2010) Gene–environment interaction between
HLA-DRB1 shared epitope and heavy cigarette smoking in predicting
incident rheumatoid arthritis. Ann. Rheum. Dis. 69, 54–60
68 Costenbader, K.H. et al. (2008) Genetic polymorphisms in PTPN22,
PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two
longitudinal cohort studies: evidence of gene–environment
interactions with heavy cigarette smoking. Arthritis Res. Ther. 10,
R52
69 Ramagopalan, S.V. et al. (2010) A ChIP-seq defined genome-wide map
of vitamin D receptor binding: Associations with disease and evolution.
Genome Res. 20, 1352–1360
70 Ramagopalan, S.V. et al. (2009) Expression of the multiple sclerosis-
associated MHC class II Allele HLA-DRB1*1501 is regulated by
vitamin D. PLoS Genet. 5, e1000369
71 Lessard, C.J. et al. (2012) The genomics of autoimmune disease in the
era of genome-wide association studies and beyond. Autoimmun. Rev.
11, 267–275
72 Mathew, C.G. (2008) New links to the pathogenesis of Crohn disease
provided by genome-wide association scans. Nat. Rev. Genet. 9, 9–14
73 Wang, K. et al. (2009) Diverse genome-wide association studies
associate the IL12/IL23 pathway with Crohn Disease. Am. J. Hum.
Genet. 84, 399–405
74 Bottini, N. et al. (2004) A functional variant of lymphoid tyrosine
phosphatase is associated with type I diabetes.Nat. Genet. 36, 337–338
75 McCarthy, M.I. et al. (2008) Genome-wide association studies for
complex traits: consensus, uncertainty and challenges. Nat. Rev.
Genet. 9, 356–369
76 Grice, E.A. and Segre, J.A. (2012) The human microbiome: our second
genome. Annu. Rev. Genomics Hum. Genet. 13, 151–170
77 Shui, J.W. et al. (2012) HVEM signalling at mucosal barriers provides
host defence against pathogenic bacteria. Nature 488, 222–225
78 Gregory, A.P. et al. (2012) TNF receptor 1 genetic risk mirrors outcome
of anti-TNF therapy in multiple sclerosis. Nature 488, 508–511
79 Hodges, E. et al. (2011) Directional DNA methylation changes and
complex intermediate states accompany lineage specificity in the adult
hematopoietic compartment. Mol. Cell 44, 17–28
80 Maier, H. et al. (2004) Early B cell factor cooperates with Runx1 and
mediates epigenetic changes associated with mb-1 transcription. Nat.
Immunol. 5, 1069–1077
81 Cobb, R.M. et al. (2006) Accessibility control of V(D)J recombination.
Adv. Immunol. 91, 45–109
82 Quintin, J. et al. (2012) Candida albicans infection affords protection
against reinfection via functional reprogramming of monocytes. Cell
Host Microbe 12, 223–232
83 Eichler, E.E. et al. (2010) Missing heritability and strategies for finding
the underlying causes of complex disease.Nat. Rev. Genet. 11, 446–450
84 Ng, S.B. et al. (2010) Massively parallel sequencing and rare disease.
Hum. Mol. Genet. 19, R119–R124
85 Netea, M.G. et al. (2012) Genetic variation in Toll-like receptors and
disease susceptibility. Nat. Immunol. 13, 535–54283
